Located along Maryland’s I-270 technology corridor, the expanded facility will accommodate Lentigen’s future growth needs as a developer and manufacturer of lentiviral vectors and proteins for a wide range of therapeutic and research applications.
Tim Ravenscroft, Lentigen’s CEO, said: “Located in the heart of Maryland’s technology corridor, we will be well situated to attract talented individuals to our growing organization and to meet the increasing needs of our partners and customers.”